KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income - MinorityNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Quest Diagnostics (DGX) Revenue: 2009-2025

Historic Revenue for Quest Diagnostics (DGX) over the last 17 years, with Sep 2025 value amounting to $2.8 billion.

  • Quest Diagnostics' Revenue rose 13.18% to $2.8 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $10.8 billion, marking a year-over-year increase of 13.74%. This contributed to the annual value of $9.9 billion for FY2024, which is 6.70% up from last year.
  • Per Quest Diagnostics' latest filing, its Revenue stood at $2.8 billion for Q3 2025, which was up 1.99% from $2.8 billion recorded in Q2 2025.
  • Quest Diagnostics' 5-year Revenue high stood at $2.8 billion for Q3 2025, and its period low was $2.3 billion during Q4 2023.
  • Moreover, its 3-year median value for Revenue was $2.4 billion (2024), whereas its average is $2.5 billion.
  • Its Revenue has fluctuated over the past 5 years, first skyrocketed by 49.29% in 2021, then decreased by 14.98% in 2022.
  • Over the past 5 years, Quest Diagnostics' Revenue (Quarterly) stood at $2.7 billion in 2021, then declined by 14.98% to $2.3 billion in 2022, then fell by 1.93% to $2.3 billion in 2023, then grew by 14.55% to $2.6 billion in 2024, then rose by 13.18% to $2.8 billion in 2025.
  • Its Revenue was $2.8 billion in Q3 2025, compared to $2.8 billion in Q2 2025 and $2.7 billion in Q1 2025.